

**Roberto Imberti, M.D.**

**CURRICULUM VITAE**

***Personal Data***

*Date of Birth*

*Place of Birth*

*Home Address*

*Mobile Phone*

*e-Mail*

*College of Physician*

*VAT number*

***Education***

1980	M.D., University of Pavia
1984	Specialty in Anesthesiology and Critical Care Medicine, University of Pavia, Italy
1988	Specialty in Pharmacology ("indirizzo Farmacologia Clinica"), University of Milano, Italy

***Foreign Languages***

*English*

Written: excellent

Spoken: sufficiently fluent

*French*

Written and spoken: basic

## **Professional Experience**

2019 - present	- Palliative Care Physician (part-time) at Fondazione Cella – Broni (PV)
2013 – 2018	Coordinatore e Responsabile Medico, Phase I Clinical Trials Unit and Experimental Therapy - Fondazione IRCCS Policlinico S. Matteo – Pavia, Italy
2011 - 2015	Responsabile Medico, Phase I Clinical Trials Unit and Experimental Therapy - Fondazione IRCCS Policlinico S. Matteo – Pavia, Italy
2009 - 2011	Direzione Scientifica, Fondazione IRCCS Policlinico, S.Matteo, Pavia, Italy
1986 - 2009	Anesthesiologist and Intesivist, Fondazione IRCCS Policlinico, S.Matteo, Pavia, Italy
1982 - 1986	Anesthesiologist and Intesivist, Spedali Civili, Brescia, Italy
1980 - 1982	Postdoctoral Fellowship, Department of Anesthesiology and Intensive Care, Fondazione IRCCS Policlinico, S.Matteo, Pavia
1989 - 1990	Postdoctoral Fellowship, Department of Cell Biology and Anatomy, University of North Carolina, CHAPEL HILL, USA

## **Honours**

1980	M.D. <i>cum laude</i>
1984	Anesthesiologist <i>cum laude</i>

## **Academics**

1993 - 1999	Assistant Professor, Anesthesiology&Critical Care Medicine, University of Pavia
2001 - 2010	Assistant Professor, Neurosurgery, University of Pavia

## **Membership**

2015 – present

Member, Società Italiana di Medicina Farmaceutica

1991 - 2015

Full member, Società Italiana di Anestesia, Analgesia, Rianimazione e Terapia Intensiva (SIAARTI).

1994 - 2000

Full Member of The Society of Toxicology (SOT), USA.

### ***Clinical Research Experience***

Principal Investigator or Co-investigator of phase I, II and III clinical studies in neurocritical care, hematology, oncology, pneumology, neurology, rare diseases, and bioavailability-bioequivalence studies (reported below)

2015-2018

Principal Investigator of the study “*Multi-dimensional omics approach to stratification of patients with low back pain (PAIN-OMICS)*”, funded by the European Community's 7th Framework Programme.

Pre-clinical development of a repurposed medicinal product for the treatment of Cystic Fibrosis which was granted with the Orphan Drug Designation by EMA in 2017

*A Phase 1/2, Open Label, Multicenter Study To Assess The Safety And Tolerability Of Durvalumab (Anti-Pd-L1 Antibody) As Monotherapy And In Combination Therapy In Subjects With Lymphoma Or Chronic Lymphocytic Leukemia. MEDI4736-NHL-001. Sponsor Celgene (Co-investigator)*

*A Phase 1b Multicenter, Open-Label Study To Determine The Recommended Dose And Regimen Of Durvalumab (Medi4736) Either As Monotherapy Or In Combination With Pomalidomide (Pom) With Or Without Lowdose Dexamethasone (Dex) In Subjects With Relapsed And Refractory Multiple Myeloma (Rrmm). MEDI4736-MM-001. Sponsor Celgene (Co-investigator)*

*A Phase 1/2 Multicenter, Open-Label Study To Determine The Recommended Dose And Regimen Of Durvalumab (Medi4736) In Combination With Lenalidomide (Len) With And Without Dexamethasone (Dex) In Subjects With Newly Diagnosed Multiple Myeloma (NDMM). MEDI4736-MM-001. Sponsor Celgene (Co-investigator)*

*A Phase 1/2, Multicenter, Open-Label, Dose Finding Study To Assess The Safety, Tolerability, And Preliminary Efficacy Of Cc-122 In Combination With Nivolumab In Subjects With Unresectable Hepatocellular Carcinoma (Hcc). CC-122-HCC-002. Sponsor Celgene (Co-investigator)*

*An Open-Label, Multi-Center, Randomized, Dose-Escalation, Phase Ib Study To Evaluate Safety, Pharmacokinetics And Therapeutic Activity Of Ro6874281 In Combination With Atezolizumab ± Bevacizumab In Patients With Unresectable Advanced And/Or Metastatic Renal Cell Carcinoma. BP39365. Sponsor Roche (Co-investigator)*

*A Phase 2, Propsective Study of PRM-151 in Subjects with Primary Myelofibrosis (PFM), Post-Polycythemia Vera (post-PV MF), or Post-Essential Thrombocythemia MF (post-ET MF). PRM-151G-101. Sponsor Promedior (Co-investigator)*

*A Phase 2, Multicenter, Open-Label Study To Evaluate The Efficacy And Safety Of Luspatercept (Ace-536) In Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis And Anemia With And Without Red Blood Cell-Transfusion Dependence. ACE-536-MF-001. Sponsor Celgene (Co-investigator)*

*A Phase 2, open label, dose regimen ranging clinical study to determine the safety and efficacy of INCB018424 in patients with advanced polycythemia vera or essential thrombocythemia refractory to hydroxyurea. INCB 18424-256. Sponsor Incyte Corporation (Co-investigator)*

*APOLLO: A Phase 3 Multicenter, Multinational, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Patisiran (ALN-TTR02) in Transthyretin (TTR)-Mediated Polyneuropathy (Familial Amyloidotic Polyneuropathy-FAP). ALN-TTR02-004. Sponsor Alnylam (Co-investigator)*

*A Multicenter, Open-Label, Extension Study To Evaluate The Long-Term Safety And Efficacy Of Patisiran In Patients With Familial Amyloidotic Polyneuropathy Who Have Completed A Prior Clinical Study With Patisiran. Aln-Ttr02-006. Sponsor Alnylam (Co-investigator)*

*A Multicentre Open label Phase II study of Daratumumab in AL Amyloidosis Patients not in VGPR or Better– the IFM 2016-02 study. Sponsor Université de Limoges (Co-investigator)*

*A Phase 2b, Randomized, Double-blind, Placebocontrolled Study of NEOD001 in Previously Treated Subjects with Light Chain (AL) Amyloidosis who have Persistent Cardiac Dysfunction. NEOD001-201. Sponsor Prothena (Co-investigator)*

*A Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled, 2-Arm, Efficacy and Safety Study of NEOD001 Plus Standard of Care vs. Placebo Plus Standard of Care in Subjects with Light Chain (AL) Amyloidosis. NEOD001-CL002. Sponsor Prothena (Co-investigator)*

*Principal Investigator of the study “Bioequivalence of a new oral Levosulpiride formulation compared with a standard one in healthy volunteers. Single centre, single dose, open label, randomized, two-way cross-over study”. Sponsor Epifarma s.r.l.*

2012-2014

*Principal Investigator of the study “Randomized two-way cross-over, open label, single center study to evaluate bioavailability, local tolerability and safety of Diclofenac diethylamine 1% gel in comparison with a reference product in healthy volunteers”. Sponsor Epifarma s.r.l.*

*Principal Investigator of the study “Randomized two-way cross-over, open label, single center study to evaluate bioavailability, local tolerability and safety of Diclofenac diethylamine 2% gel in comparison with a reference product in healthy volunteers”. Sponsor Epifarma s.r.l.*

Principal Investigator of the study “*Bioequivalence of a new oral Ibuprofen 600 mg formulation compared with a standard one on healthy volunteers*”. Sponsor Epifarma s.r.l.

*Randomized cross-over, open label, single center, controlled versus reference products study to evaluate bioavailability, local skin tolerability and adhesiveness of a new topical formulation of diclofenac diethylamine 40.65 mg and thiocolchicoside 2.5 mg patch in healthy volunteers.* Sponsor Epifarma s.r.l. (Co-investigator)

*Randomized cross-over, single blind, single dose, single center study to compare, after Intramuscular administration in healthy volunteers, the bioavailability, safety and local tolerability of a new fixed dose combination injectable formulation of Diclofenac sodium 75 mg and Thiocolchicoside 4 mg with co-administered reference single-agent formulations.* Sponsor Epifarma s.r.l. (Co-investigator)

*Exploratory, prospective longitudinal biomarker trial in patients with asthma, COPD, autoimmune pulmonary alveolar proteinosis (PAP) and healthy volunteers to investigate biomarkers potentially associated with PAP.* Sponsor Boehringer Ingelheim (Co-investigator)

*Randomized cross-over, open label, single center, controlled versus competitor, phase I study to evaluate local tolerability and bioequivalence of a new formulation of flurbiprofen 8.75 mg lozenges in healthy volunteers.* Sponsor Epifarma s.r.l. (Co-investigator)

*Bioavailability of a new oral Levosulpiride formulation compared with a standard one on healthy volunteer. Single dose, open, randomized, two-way cross-over, two stage design-bioequivalence study.* Sponsor Epifarma s.r.l. (Co-investigator)

2010

Coordinating Investigator of a spontaneous study named “*Early and Late Evaluation of ICP in Poor Grade Patients with Aneurysmal Subarachnoid Hemorrhage. Prospective Observational Study*”. Fondazione IRCCS Policlinico S. Matteo, Pavia

2009

Coordinating Investigator of a spontaneous study named “*Pharmacokinetics of colistin in cerebrospinal fluid after intraventricular administration of colistin methanesulfonate*”. Fondazione IRCCS Policlinico S. Matteo, Pavia

2008

Coordinating Investigator of a spontaneous study named “*Efficacy and safety of recombinant Factor VIIa (Eptagog alfa, NovoSeven, Novo Nordisk) on rebleeding after surgery for spontaneous supratentorial intracerebral hemorrhage. A randomized, controlled, open-label, investigator-blinded study*”. Fondazione IRCCS Policlinico S. Matteo, Pavia

Principal Investigator of a spontaneous study named “*Steady-state pharmacokinetics and bronchoalveolar lavage concentration of colistin in critically ill patients after intravenous colistin methanesulphonate administration*”. Fondazione IRCCS Policlinico S. Matteo, Pavia

2007

Coordinating Investigator of a spontaneous study named “*Efficacy of thalamic stimulation in the treatment of vegetative state and minimal conscious state*” .  
Fondazione IRCCS Policlinico S. Matteo, Pavia

2000-2007

*Participation to 3 clinical studies as Local Investigator, sponsored by Sandoz, Bayer, and Pharmos performed in patients with severe traumatic brain injury.*

### ***Scientific Activity***

Consultant for the Ethics Committee, Fondazione IRCCS Policlinico, S. Matteo, Pavia, for clinical studies in Critical Care

Reviewer for

*The New England Journal of Medicine, Intensive Care Medicine, Stroke, Brain, Child’s Nervous System, Archives of Medical Sciences, Journal of Antimicrobial Chemotherapy, Journal of Infection and Chemotherapy, Infectious Disease Reports, Int J Infectious Dis, BMC Microbiology, Clinical Microbiology and Infection, Exp Opin Drug Safety, PlosONE, Pediatric Journal of Infectious Diseases, NeuroCritical Care*

## **RELEVANT PUBLICATIONS** (by date)

### **Pharmacology, Toxicology, Mechanisms of Cell and Tissue Injury**

- Fabris N, Mochelegiani E, Muzzioli M, **Imberti R**: Thymus-neuroendocrine network. In: *"Immunoregulation"*. Fabris N, Garaci E, Hadden J, Mitchinson NA, eds. Plenum Press, 1983, 341-362.
- Preseglio I, Domenegati E, **Imberti R**, Regazzi MB, Bartoli A, Gratarola A: Livelli plasmatici di bupivacaina nell'anestesia venosa retrograda. *Acta Anaesth Ital*, 1988, 39, 259-264.
- Nieminen A-L, Gores GJ, **Imberti R**, Herman B and Lemasters JJ: Assessment of Cell Death in Hypoxic Cell Injury. In: *Mechanisms of Injury, Protection and Repair of the Upper Gastrointestinal Tract*. A. Garner and P.E. O'Brian, eds. Wiley & Sons, p.47-59, 1990.
- Imberti R**, Mapelli A, Colombo P, Richelmi P., Berte' F, Bellomo G: 1,2-Dichloropropane (DCP) toxicity is correlated with DCP-induced glutathione (GSH) depletion and is modulated by factors affecting intracellular GSH. *Arch Toxicol*, 1990, 64, 459-465.
- Imberti R**, Nieminen A-L, Herman B and Lemasters JJ: Synergism of cyclosporin A and phospholipase inhibitors in protection against lethal injury to rat hepatocytes from oxidant chemicals. *Research Commun Chem Path Pharmacol*, 1992, 78, 27-38.
- Nieminen A-L, Gores GJ, Bond JM, **Imberti R**, Herman B and Lemasters JJ: A novel cytotoxicity screening assay using a multi-well fluorescence scanner. *Toxicol Appl Pharmacol*, 1992, 115, 147-155.
- Imberti R**, A-L Nieminen, B. Herman and JJ Lemasters. Mitochondrial and glycolytic disfunction in lethal injury to hepatocytes by *t*-Butyl hydroperoxide: protection by fructose, cyclosporin A and trifluoperazine. *J Pharmac Exper Therapeut*, 1993, 265, 392-400.
- Lemasters JJ, Nieminen A-L, Chacon E, **Imberti R**, Gores GJ, Reece JM, and Herman B: Use of fluorescent probes to monitor mitochondrial membrane potential in isolated mitochondria, cell suspensions, and cultured cells. *Methods in Toxicology*, LH Lash and DP Jones, eds. Academic Press 1993, vol. 2, p. 404-415.
- Imberti R**, Vairetti M, Richelmi P, Preseglio I and Bellomo G: Thyroxine pretreatment and halothane administration alter Ca<sup>2+</sup> transport and transmembrane potential in rat liver mitochondria. An additional mechanism for halothane-induced liver damage in the hyperthyroid rat model. *Arch Toxicol*, 1994, 68, 103-109.
- Nieminen A-L, **Imberti R**, Saylor AK, Tesfai SA, Herman B and Lemasters JJ. Role of mitochondrial injury during oxidative injury to hepatocytes: evidence of a mitochondrial permeability transition by laser scanning confocal microscopy. In *'Cell Biology of Trauma'*, JJ Lemasters and C Oliver, Eds., CRC Press, Boca Raton, Florida, 1995, p. 49-62.
- Imberti R**, Vairetti M, Silini E, Richelmi P, Bertè F. Effects of thyroid hormone modulation on rat liver injury associated with anoxia, oxidative stress and cold storage. *Haematologica* 1998, **83** (suppl), 46-47. IF 1.876

- Imberti R**, Vairetti M, Gualea M, Feletti F, Poma G, Richelmi P, Preseglio I. Effects of thyroid hormone modulation on rat liver injury associated with ischemia-reperfusion and cold storage. *Anesth Analg* 1998, **86**, 1187-93. IF 2.776
- Vairetti M, Richelmi P, Bertè F, Currin RT, Lemasters JJ, **Imberti R**. Role of pH in protection by low sodium against hypoxic injury in isolated perfused rat livers. *J Hepatol* 2006, 44, 894-901. IF 6.642
- Vairetti M, Ferrigno A, Rizzo V, Richelmi P, Cillo U, **Imberti R**. Liver damage during ischemia/reperfusion and glutathione: implications for potential organ donors. *Transplant Proc* 2007, 39:1768-70. IF 1.027
- Imberti R**, Cusato M, Villani P, Carnevale L, Iotti GA, Langer M, Regazzi M. Steady-state pharmacokinetics and bronchoalveolar lavage concentration of colistin in critically ill patients after intravenous colistin methanesulphonate administration. *Chest* 2010;138:1333-9. IF 6.519
- Imberti R**. Intravenous colistimethate administration and colistin lung tissue concentration (letter). *Intensive Care Med* 2010;36:1795. IF 2.098
- Imberti R**, Iotti GA, Cusato M, Regazzi M. Colistin penetration in the alveolar lining fluid of critically ill patients treated with iv colistimethate sodium (letter). *Chest* 2011, 139, 233-234. IF 5.250
- Imberti R**, Iotti GA, Cusato M, Regazzi M. Colistin use in critically ill patients. In search for the optimal dosing (letter). *Chest* 2011, 139, 234-235. IF 5.250
- Antonella Natalia Bartoli, Simona De Gregori, Mariadelfina Molinaro, Monica Broglia, Carmine Tinelli and **Roberto Imberti**. Bioavailability of a New Oral Spray Melatonin Emulsion Compared with a Standard Oral Formulation in Healthy Volunteers. *J Bioequiv Availab* 2012, 4(7):096-099.
- Imberti R**, Cusato M, Accetta G, Marinò V, Procaccio F, Del Gaudio A, Iotti GA, Regazzi M. Pharmacokinetics of colistin in cerebrospinal fluid after intraventricular administration of colistin methanesulfonate. *Antimicrob Agents Chemother* 2012; 56:4416-21. IF 4.565
- Imberti R**, Ferrigno A, Tartaglia A, Rizzo V, Richelmi P, Vairetti M. Changes in extra- and intracellular pH in hepatocytes exposed to gabexate mesilate. *Int J Immunopathol Pharmacol* 2014;27(3):365-70. IF 1.617
- Imberti R**, De Gregori S, Lisi L, Navarra P. Influence of the oral dissolution time on the absorption rate of locally administered solid formulations for oromucosal use: the flurbiprofen lozenges paradigm. *Pharmacology* 2014;94(3-4):143-7. IF 1.672
- Narongsak Nakwan, Pichaya Lertpichaluk, Kulkanya Chokeyhaibulkit, Paola Villani, Mario Regazzi, **Roberto Imberti**. Pulmonary and systemic pharmacokinetics of colistin following a single dose of nebulized colistimethate in mechanically ventilated neonates. *Ped J Infect Dis*, 2015, 34(9):961-3. IF 2.587
- Percivalle E, Monzillo V, Pauletto A, Marone P, **Imberti R**. Colistin inhibits E. coli O157:H7 Shiga-like toxin release, binds endotoxins and protects Vero cells. *New Microbiol* 2016 Feb;39(2):119-23. IF 1.603



- Nakwan N, Usaha S, Chokephaibulkit K, Villani P, Regazzi M, **Imberti R**. Pharmacokinetics of Colistin Following a Single Dose of Intravenous Colistimethate Sodium in Critically Ill Neonates. *Pediatr Infect Dis J* 2016, 35(11):1211-1214. IF2.486
- De Gregori S, Cipollina L, De Silvestri A, Ventura M, Michelini R, Morosini M, Montagna M, Tinelli C, Regazzi M, Molinaro M, **Imberti R**. Bioequivalence of a New Oral Levosulpiride Formulation Compared With a Standard One in Healthy Volunteers. *Ther Drug Monit* 2017 Apr;39(2):118-123. IF 2.092
- Imberti R**, Garavaglia ML, Verduci I, Cannavale G, Balduzzi G, Papetti S, Mazzanti M. Antiestrogen- and tamoxifen-induced effects on calcium-activated chloride currents in epithelial cells carrying the  $\Delta F508$ -CFTR point mutation. *Respir Res* 2018, 19(1):198. IF 3.829
- Imberti R**, De Gregori S, Rabaglia L, Regazzi M. Bioavailability of a fixed combination of intramuscular diclofenac 75 mg + thiocolchicoside 4 mg single dose vs. single components. *Minerva Med* 2019 Jun;110(3):264-267. IF 3.0

### **Critical Care Medicine**

- Schiavina M, De Palma R, Cirignotta F, Mondini S, Sturani C, **Imberti R**: Ipoventilazione alveolare centrale (Maledizione di Ondine): osservazione di un caso. *Riv Pat Clin Tuberc Pneumol*, 1985, 56, 663-676.
- Imberti R**, Calabrese SR, Emilio G, Marchi L, Giuffrida L: Intossicazione acuta da solventi: idrocarburi alifatici alogenati. *Min Anesthesiol*, 1987, 53, 399-403.
- Imberti R**, Locatelli D, Fanzio M, Bonfanti M, Preseglio I: Intra- and postoperative management of craniosynostosis. *Can J Anaesth*, 1990, 37, 948-949.
- Imberti R**, Filisetti P, Preseglio I, Mapelli A, Spriano P: Confirmation of brain death utilizing Thyrotropin-Releasing Hormone stimulation test. *Neurosurgery*, 1990, 27, 167.
- Imberti R**, Bellinzona G, Poggi N, Ilardi M, Favaro L, Raimondi M, Carnevale L, Preseglio I, Stomeo G. Effect of indomethacin on uncontrolled intracranial hypertension in patients with severe head injury. *Min Anesthesiol* 1995, 61 (suppl.2), 157.
- Mocchegiani E, **Imberti R**, Testasecca D, Zandri M, Santarelli L, Fabris N. Thyroid and thymic endocrine function and survival in severely traumatized patient with or without head injury. *Intensive Care Med* 1995, 21, 334-341.
- Brambilla G, Sangiovanni G, **Imberti R**, Bernocchi G, and Curti D: Alteration of cholinergic activity in experimental severe spinal cord injury. *J Neurosurg Sci* 1996, **40**, 213-219.
- Imberti R**, Bellinzona G, Ilardi M, Bruzzone P, Pricca P. The use of indomethacin to treat acute rises of intracranial pressure and improve global cerebral perfusion in a child with head trauma. *Acta Anaesth Scand* 1997, **41**, 536-540. IF 1.180
- Bruzzone P, Dionigi R, Bellinzona G, **Imberti R** and Stocchetti N: Effects of cerebral perfusion pressure on brain tissue PO<sub>2</sub> in patients with severe head injury. *Acta Neurochir* 1998, 71(suppl), 111-113. IF 0.748
- Imberti R**, Ciceri M, Bellinzona G, Pugliese R. The use of hyperventilation in the treatment of plateau waves in two patients with severe traumatic brain injury: contrasting effects on brain oxygenation. *J Neurosurg Anesthesiol* 2000, 12, 124-127. IF 0.959
- Imberti R**, Bellinzona G, Langer M. Cerebral tissue PO<sub>2</sub> and SjvO<sub>2</sub> changes during moderate hyperventilation in patients with severe traumatic brain injury. *J Neurosurg* 2002, 96, 97-102. IF 2.626
- Imberti R**, Bellinzona G, Langer M. Traumatic brain injury and hyperventilation (letter). *J Neurosurg* 2002, 96, 156-157. IF 2.626
- Imberti R**, Bellinzona G, Langer M. Hyperventilation (letter). *J Neurosurg* 2002, 97, 1002. IF 2.626
- Imberti R**, Bellinzona G, Riccardi F, Pagani M, Langer M. Cerebral perfusion pressure and cerebral tissue oxygen tension in a patient during cardiopulmonary resuscitation. *Intensive Care Med* 2003. 29, 1016-1019. IF 2.971
- Imberti R**. Why have recent trials on neuroprotective agents in head injury failed to show convincing efficacy? A pragmatic analysis and theoretical considerations (letter). *Neurosurgery* 2003, 53, 241-242. IF 2.338

- Imberti R**, Fuardo M, Bellinzona G, Pagani M, Langer M: The use of indomethacin in the treatment of plateau waves: effects on cerebral perfusion and oxygenation. *J Neurosurg* 2005, 102, 455-459. IF 2.446
- Imberti R**, Langer M. Indomethacin (letter). *J Neurosurg* 2005, 103, 580-581. IF 2.446
- Imberti R**, Vairetti M: Organ donor management recommendations (letter). *CMAJ Can Med Assoc J*, 2007, 176, 1737. IF 7.067
- Imberti R**, Pricca P, Pietrobono L, Langer M. Extensive endobronchial calcification in a tetraplegic patient (letter). *Anesthesia and Analgesia*, 2007, 105: 551-2. IF 2.214
- Imberti R**, Amatu A, Scagnelli P. Post-traumatic pulmonary and cerebral fat embolism (letter). *Anaesth Int Care* 2008, 36, 619-621. IF 0.848
- Arpesella R, Dallochio C, Arbasino C, **Imberti R**, Martinotti R, Frucht JS. A patient with intractable posthypoxic myoclonus (Lance-Adams syndrome) treated with sodium oxybate. *Anaesth Int Care* 2009, 37, 314-318. IF 1.108
- Imberti R**, Ferrari M, Albertini R, Rizzo V, Tinelli C. Increased levothyroxine requirements in critically ill patients with hypothyroidism. *Minerva Anestesiol* 2010, 76, 500-3. IF 2.851
- Casiraghi G, Poli D, Landoni G, Buratti L, **Imberti R**, Plumari V, Turi S, Mennella R, Messina M, Covello RD, Carozzo A, Motta A, Zangrillo A.. Intrathecal Lactate Concentration and Spinal Cord Injury in Thoracoabdominal Aortic Surgery. *J Cardiothorac Vasc Anest* 2011;25:120-6. IF 1.640
- Imberti R**, Pietrobono L, Klersy C, Gamba G, Iotti G, Cornara G. Intraoperative intravenous administration of rFVIIa and hematoma volume after early surgery for spontaneous intracerebral hemorrhage: a randomized prospective phase II study. *Minerva Anestesiol* 2012;78:168-75. IF 2.818
- Imberti R**, Iotti GA, Regazzi M. Intraventricular or intrathecal colistin for the treatment of central nervous system infections caused by multidrug-resistant Gram-negative bacteria. *Expert Rev Anti Infect Ther* 2014;12(4):471-8. IF 3.461
- Imberti R**. Severe disability (letter). *J Neurosurg*, 2012 116(3):689-90. IF 3.148
- Di Perri C, Bastianello S, Bartsch AJ, Pistarini C, Maggioni G, Magrassi L, **Imberti R**, Pichiecchio A, Vitali P, Laureys S, Di Salle F. Limbic hyperconnectivity in the vegetative state. *Neurology* 2013, 81(16):1417-24. IF 8.303
- Mojoli F, Iotti GA, **Imberti R**, Braschi A. The importance of protecting the mechanical ventilator during colistin methanesulfonate nebulization (letter). *Intensive Care Med* 2013, 39, 535-6. IF 5.544
- Magrassi L, Maggioni G, Pistarini C, Di Perri C, Bastianello S, Zippo AG, Iotti GA, Biella GE, **Imberti R**. Results of a prospective study (CATS) on the effects of thalamic stimulation in minimally conscious and vegetative state patients. *J Neurosurg* 2016, 8:1-10. IF 4.059
- Magrassi L, Zippo AG, Azzalin A, Bastianello S, **Imberti R**, Biella GEM. Single unit activities recorded in the thalamus and the overlying parietal cortex of subjects affected by disorders of consciousness. *PLoS One* 2018 Nov 7;13(11):e0205967. IF 2.776

- Nakwan N, Chokephaibulkit K, **Imberti R**. The Use of Colistin for the Treatment of Multidrug-resistant Gram-negative Infections in Neonates and Infants: A Review of the Literature. *Pediatr Infect Dis J* 2019 Nov;38(11):1107-1112. IF 2.216
- Merico V, Imberti JF, Zanoni M, Boriani G, Garagna S, **Imberti R**. Inhibition of lysyl oxidase stimulates TGF- $\beta$  signaling and metalloproteinases-2 and -9 expression and contributes to the disruption of ascending aorta in rats: protection by propylthiouracil. *Heart Vessels* 2021 May;36(5):738-747. IF 1.814
- Imberti R**, Picetti E, Rossi S, Capaccio E, Accetta G, Klersy C, Lafe E, Pietrobono L, Cimino F, Frattini L, Grappa E, Casagli S, Crobeddu E, Iotti GA. Intracranial Pressure Monitoring in Poor-Grade Patients with Aneurysmal Subarachnoid Hemorrhage Treated by Coiling. *World Neurosurg* 2021 Sep 11:S1878-8750(21)01356-5. IF 2.210

### **Anesthesia and Pain Therapy**

- Bonezzi C, **Imberti R**, Navazio Cassa G, Pagani I, Canal M, Preseglio I: Il blocco neurologico del 3° ganglio simpatico toracico: efficacia e problematica nella terapia antalgica dell'arto superiore. *Boll Soc Med Chir Pavia*, 1984, 98, 97-100.
- Imberti R**, Maira G, Confortini MC, Preseglio I, Domenegati E: Effect of fentanyl-oxygen cardiac surgery on serum-thyroid hormones. *Acta Anaesth Belg*, 1988, 39, 217-222.
- Preseglio I, Domenegati E, **Imberti R**, Gratarola A, Adduci D, Mendola C, Mapelli A: Recupero intraoperatorio del sangue mediante separatore cellulare (Autotrans BT795/A) in chirurgia vascolare e traumatologica d'urgenza. *Min Anesthesiol*, 54, 5-8, 1988.
- Miotti D., Demartini L., Canovi M., **Imberti R.**, Pagani I., Bonezzi C.: I blocchi endovenosi periferici del sistema nervoso simpatico nelle algodistrofie. *Boll Soc Med Chir Pavia*, 1989, 103, 423-430.
- Filisetti P, Marracini P, Santagostino G, Preseglio I, Fanzio M, **Imberti R**, Mapelli A, Franco G. Acido D-Glucarico. Una nuova metodica proposta per indagare il danno da esposizione a gas e vapori anestetici. *Min Anesthesiol* 1990, 56, 1419-1424.
- Imberti R**, Preseglio I, Trotta V, Filisetti P, Mapelli A: Blood transfusion during Cesarean Section. A 12 years retrospective analysis. *Acta Anaesth Belgica*, 1990, 41, 139-144.
- Imbriani M., Ghittori S., Zadra P. and **Imberti R.** Biological monitoring of the occupational exposure to halothane (Fluothane) in operating room personnel. *Am J Ind Med* 1991, 20,103-112.
- Imberti R**, Bonfanti N, Fanzio M, Locatelli D, Preseglio I. Trattamento anestesilogico e perioperatorio dei pazienti affetti da craniosinostosi. *Anest Rianim Int*, 1992, 3, 35-39.
- Imbriani M, Andreoletti F, Baj A, Bolzoni G, Buratti M, Cantoni S, Cecchetti R, Colombi A, Ghittori S, **Imberti R**, Mosconi G. Measurements and environmental and biological monitoring of occupational exposure to inhalation anesthetics. *G Ital Med Lav* 1992, 14, 11-24.
- Imberti R**, Preseglio I, Verde G. Bedside APTT and PT monitoring. *Br J Anaesth*, 1993, 71, 164.
- Imberti R**, Preseglio I, Imbriani M, Ghittori S, Cimino F, Mapelli A. Low flow anaesthesia reduces occupational exposure to inhalation anaesthetics. Environmental and biological measurements in operating room personnel. *Acta Anaesthesiol Scand*, 1995 Jul;39(5):586-91.
- Imberti R**, Preseglio I, Giordano A, Scandone M, Mapelli P, Imbriani M, Ghittori S. Low flow anesthesia reduces anesthetic pollution in a non-ventilated dental room. *Min Anesthesiol* 1996, 62(suppl.2), 18.
- Alessio A, Zadra P, Negri S, Maestri L, **Imberti R**, Ghittori S, Imbriani M, Cavalleri A. Monitoraggio biologico dell'esposizione occupazionale a Desflurane. *G Ital Med Lav Erg* 2003, 25:2, 137-141.

Pavia, 10. 08. 2022

Roberto Imberti, MD

In accordance with the personal data protection law n° 196/2003